BACKGROUND: The effect of alcohol on liver disease in HIV infection has not been well characterized. METHODS: We performed a cross-sectional multivariable analysis of the association between lifetime alcohol use and liver fibrosis in a longitudinal cohort of HIV-infected patients with alcohol problems. Liver fibrosis was estimated with 2 noninvasive indices, "FIB-4," which includes platelets, liver enzymes, and age; and aspartate aminotransferase/platelet ratio index ("APRI"), which includes platelets and liver enzymes. FIB-4 <1.45 and APRI <0.5 defined the absence of liver fibrosis. FIB-4 >3.25 and APRI >1.5 defined advanced liver fibrosis. The main independent variable was lifetime alcohol consumption (<150 kg, 150 to 600 kg, >600 kg). RESULTS: Subjects (n = 308) were 73% men, mean age 43 years, 49% with hepatitis C virus (HCV) infection, 60% on antiretroviral therapy, 49% with an HIV RNA load <1,000 copies/ml, and 18.7% with a CD4 count <200 cells/mm(3) . Forty-five percent had lifetime alcohol consumption >600 kg, 32.7% 150 to 600 kg, and 22.3% <150 kg; 33% had current heavy alcohol use, and 69% had >9 years of heavy episodic drinking. Sixty-one percent had absence of liver fibrosis and 10% had advanced liver fibrosis based on FIB-4. In logistic regression analyses, controlling for age, gender, HCV infection, and CD4 count, no association was detected between lifetime alcohol consumption and the absence of liver fibrosis (FIB-4 <1.45) (adjusted odds ratio [AOR] = 1.12 [95% CI: 0.25 to 2.52] for 150 to 600 kg vs. <150 kg; AOR = 1.11 [95% CI: 0.52 to 2.36] for >600 kg vs. <150 kg; global p = 0.95). Additionally, no association was detected between lifetime alcohol use and advanced liver fibrosis (FIB-4 >3.25). Results were similar using APRI, and among those with and without HCV infection. CONCLUSIONS: In this cohort of HIV-infected patients with alcohol problems, we found no significant association between lifetime alcohol consumption and the absence of liver fibrosis or the presence of advanced liver fibrosis, suggesting that alcohol may be less important than other known factors that promote liver fibrosis in this population.
BACKGROUND: The effect of alcohol on liver disease in HIV infection has not been well characterized. METHODS: We performed a cross-sectional multivariable analysis of the association between lifetime alcohol use and liver fibrosis in a longitudinal cohort of HIV-infectedpatients with alcohol problems. Liver fibrosis was estimated with 2 noninvasive indices, "FIB-4," which includes platelets, liver enzymes, and age; and aspartate aminotransferase/platelet ratio index ("APRI"), which includes platelets and liver enzymes. FIB-4 <1.45 and APRI <0.5 defined the absence of liver fibrosis. FIB-4 >3.25 and APRI >1.5 defined advanced liver fibrosis. The main independent variable was lifetime alcohol consumption (<150 kg, 150 to 600 kg, >600 kg). RESULTS: Subjects (n = 308) were 73% men, mean age 43 years, 49% with hepatitis C virus (HCV) infection, 60% on antiretroviral therapy, 49% with an HIV RNA load <1,000 copies/ml, and 18.7% with a CD4 count <200 cells/mm(3) . Forty-five percent had lifetime alcohol consumption >600 kg, 32.7% 150 to 600 kg, and 22.3% <150 kg; 33% had current heavy alcohol use, and 69% had >9 years of heavy episodic drinking. Sixty-one percent had absence of liver fibrosis and 10% had advanced liver fibrosis based on FIB-4. In logistic regression analyses, controlling for age, gender, HCV infection, and CD4 count, no association was detected between lifetime alcohol consumption and the absence of liver fibrosis (FIB-4 <1.45) (adjusted odds ratio [AOR] = 1.12 [95% CI: 0.25 to 2.52] for 150 to 600 kg vs. <150 kg; AOR = 1.11 [95% CI: 0.52 to 2.36] for >600 kg vs. <150 kg; global p = 0.95). Additionally, no association was detected between lifetime alcohol use and advanced liver fibrosis (FIB-4 >3.25). Results were similar using APRI, and among those with and without HCV infection. CONCLUSIONS: In this cohort of HIV-infectedpatients with alcohol problems, we found no significant association between lifetime alcohol consumption and the absence of liver fibrosis or the presence of advanced liver fibrosis, suggesting that alcohol may be less important than other known factors that promote liver fibrosis in this population.
Authors: Jason T Blackard; Jeffrey A Welge; Lynn E Taylor; Kenneth H Mayer; Robert S Klein; David D Celentano; Denise J Jamieson; Lytt Gardner; Kenneth E Sherman Journal: Clin Infect Dis Date: 2011-01-19 Impact factor: 9.079
Authors: Erin M McCartney; Ljiljana Semendric; Karla J Helbig; Susan Hinze; Brett Jones; Steven A Weinman; Michael R Beard Journal: J Infect Dis Date: 2008-12-15 Impact factor: 5.226
Authors: Christopher W Kahler; Tao Liu; Patricia A Cioe; Vaughn Bryant; Megan M Pinkston; Erna M Kojic; Nur Onen; Jason V Baker; John Hammer; John T Brooks; Pragna Patel Journal: AIDS Behav Date: 2017-07
Authors: Joseph K Lim; Janet P Tate; Shawn L Fultz; Joseph L Goulet; Joseph Conigliaro; Kendall J Bryant; Adam J Gordon; Cynthia Gibert; David Rimland; Matthew Bidwell Goetz; Marina B Klein; David A Fiellin; Amy C Justice; Vincent Lo Re Journal: Clin Infect Dis Date: 2014-02-25 Impact factor: 9.079
Authors: Natalie E Kelso-Chichetto; Michael Plankey; Alison G Abraham; Nicole Ennis; Xinguang Chen; Robert Bolan; Robert L Cook Journal: Am J Drug Alcohol Abuse Date: 2017-06-16 Impact factor: 3.829
Authors: H Nina Kim; Heidi M Crane; Carla V Rodriguez; Stephen Van Rompaey; Kenneth H Mayer; Katerina Christopoulos; Sonia Napravnik; Geetanjali Chander; Heidi Hutton; Mary E McCaul; Edward R Cachay; Michael J Mugavero; Richard Moore; Elvin Geng; Joseph J Eron; Michael S Saag; Joseph O Merrill; Mari M Kitahata Journal: AIDS Behav Date: 2017-07
Authors: Christopher W Kahler; David W Pantalone; Nadine R Mastroleo; Tao Liu; Gerald Bove; Bharat Ramratnam; Peter M Monti; Kenneth H Mayer Journal: J Consult Clin Psychol Date: 2018-08
Authors: Emily C Williams; Judith A Hahn; Richard Saitz; Kendall Bryant; Marlene C Lira; Jeffrey H Samet Journal: Alcohol Clin Exp Res Date: 2016-09-22 Impact factor: 3.455
Authors: Daniel Fuster; Judith I Tsui; Debbie M Cheng; Emily K Quinn; Kaku A Armah; David Nunes; Matthew S Freiberg; Jeffrey H Samet Journal: AIDS Res Hum Retroviruses Date: 2013-05-17 Impact factor: 2.205
Authors: Daniel Fuster; Kaku So-Armah; Debbie M Cheng; Sharon M Coleman; Natalia Gnatienko; Dmitry Lioznov; Evgeny M Krupitsky; Matthew S Freiberg; Jeffrey H Samet Journal: Curr HIV Res Date: 2021 Impact factor: 1.341